June 6, 2022
Did we learn anything?
There comes a time when you realize that for all the progress being made far too often it’s two steps forward and one step backwards. This is our takeaway from ADA. Going in we expected more excitement – there was the rumored Dexcom Insulet deal – the FDA approval of Libre3 – Lilly’s new drug and this was the first live in person domestic event in two years.
What we got was more of the same and the realization that conferences such as these are becoming obsolete in their present form. The show floor was devoid of buzz and people . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.